Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas. (October 2020)

Record Type:: Journal Article
Title:: Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas. (October 2020)
Main Title:: Milademetan, an oral MDM2 inhibitor, in well-differentiated/ dedifferentiated liposarcoma: results from a phase 1 study in patients with solid tumors or lymphomas
Authors:: Gounder, M.M.
Bauer, T.M.
Schwartz, G.K.
LoRusso, P.
Kumar, P.
Kato, K.
Tao, B.
Hong, Y.
Patel, P.
Hong, D.
Abstract:
Is Part Of:: European journal of cancer. Volume 138(2020)Supplement 2
Journal:: European journal of cancer
Issue:: Volume 138(2020)Supplement 2
Issue Display:: Volume 138, Issue 1 (2020)
Year:: 2020
Volume:: 138
Issue:: 1
Issue Sort Value:: 2020-0138-0001-0000
Page Start:: S3
Page End:: S4
Publication Date:: 2020-10
Subjects:: Cancer -- Periodicals
Neoplasms -- Periodicals
Cancer -- Périodiques
Cancer
Tumors
Electronic journals
Periodicals
Electronic journals
616.994
Journal URLs:: http://www.sciencedirect.com/science/journal/09598049 ↗
http://rzblx1.uni-regensburg.de/ezeit/warpto.phtml?colors=7&jour_id=2879 ↗
http://www.clinicalkey.com/dura/browse/journalIssue/09598049 ↗
http://www.clinicalkey.com.au/dura/browse/journalIssue/09598049 ↗
http://www.elsevier.com/journals ↗
DOI:: 10.1016/S0959-8049(20)31080-7 ↗
Languages:: English
ISSNs:: 0959-8049
Deposit Type:: Legaldeposit
View Content:: Available online (eLD content is only available in our Reading Rooms) ↗
Physical Locations:: British Library DSC - 3829.725100
British Library DSC - BLDSS-3PM
British Library STI - ELD Digital store
Ingest File:: 15526.xml